February 18, 2022

The Honorable Roger Wicker  
The Honorable Amy Klobuchar  
U.S. Senate  
The Honorable Brad Wenstrup  
U.S. Senate  
555 Dirksen Senate Office Building  
425 Dirksen Senate Building  
Washington, DC 20510  
2419 Rayburn House Office Building  
Washington, DC 20515

The Honorable Doris Matsui  
The Honorable Amy Klobuchar  
House of Representatives  
The Honorable Amy Klobuchar  
2311 Rayburn House Office Building  
2311 Rayburn House Office Building  
Washington, DC 20515

RE: Support for the BENEFIT Act of 2021 (S. 373 and H.R. 4472)

Dear Senators Wicker and Klobuchar and Representatives Matsui and Wenstrup:

Thank you for your tireless efforts to encourage development of and expand access to treatments and cures for patients, including those with rare diseases. On behalf of the undersigned patient advocacy organizations, we write in strong support of your legislation, the Better Empowerment Now to Enhance Framework and Improve Treatments (BENEFIT) Act of 2021, S. 373 and H.R. 4472.

As you know, the 21st Century Cures Act (P.L. 114-255) includes sections 3001 and 3002, the Patient-Focused Impact Assessment (PFIA), which has accelerated the field of patient-focused drug development (PFDD). FDA now has a number of programs and policies in place to gather and assess patient perspectives within the regulatory review process, and patient advocacy organizations have been deeply engaged with the FDA over the past several years to develop PFDD tools that produce scientifically valid patient experience information. Tremendous progress has been made over the past decade since the fifth Prescription Drug User Fee Act (PDUFA) was authorized, including with PFIA and other provisions of 21st Century Cures. Now is the time to take the next step in moving patient perspectives and experience forward by enacting the BENEFIT Act.

The BENEFIT Act would require FDA to include in the benefit-risk assessment framework of a new drug application how patient experience data was considered in the review process. Currently, FDA includes patient experience data in reviews, but does not indicate how such data impacted the drug approval. Providing this information to the public, and patient communities making significant investments in developing PFDD, builds on transparency from PFIA and will accelerate PFDD strategies more broadly.

The field of patient engagement in drug development continues to flourish thanks to the continued interest and focus by Congress. The BENEFIT Act will build upon this foundation and fill a gap by appropriately disclosing how this data is considered as part of FDA review of new therapies. The BENEFIT Act initially passed the Senate in 2017 but further action was deferred as the 21st Century Cures was being implemented.

Now is the time to take this critical step in building the PFDD environment by passing the BENEFIT Act. The Cures 2.0 Act recognizes this as well by including a parallel provision to the BENEFIT Act. Thank you again for your leadership and we look forward to working with you to enact this legislation this Congress.

Sincerely,
Alport Syndrome Foundation
ALS Association
Alstrom Syndrome International
Ara Parseghian Medical Research Foundation
Barth Syndrome Foundation
Best Day Ever Foundation
Beyond Celiac
Casimir LLC
Coalition Duchenne
CSNK2A1 Foundation
Cure CMD
Cure HHT
Cure Sanfilippo Foundation
Cure SMA
CureDuchenne
Dravet Syndrome Foundation
Dup15q Alliance
Emily's Entourage
EveryLife Foundation for Rare Diseases
FND Hope
FORCE: Facing Our Risk of Cancer Empowered
Foundation for Prader-Willi Research
Foundation to Eradicate Duchenne
Genetic Alliance
Global Liver Institute
Hannah's Hope Fund
Hemophilia Federation of America
Hope For Marian
Immune Deficiency Foundation
International Pemphigus and Pemphigoid Foundation
Jett Foundation
Kindness Over Muscular Dystrophy
Little Hercules Foundation
Little Miss Hannah Foundation
Lupus Foundation of America
M-CM Network
MLD Foundation
National Ataxia Foundation
National Multiple Sclerosis Society
National Niemann Pick Disease Foundation
NBIA Disorders Association
Organic Acidemia Association
Parent Project Muscular Dystrophy
Phelan-McDermid Syndrome Foundation
PXE International
RASopathies Network
Rivkin Center for Ovarian Cancer
RUNX1 Research Program
Ryan’s Quest
Samantha Search for the Cure
Siegel Rare Neuroimmune Association
SYNGAP1 Foundation
The Firefly Fund
The Life Raft group
The Sudden Arrhythmia Death Syndromes (SADS) Foundation
Team Joseph
Tuberous Sclerosis Alliance
Usher 1F Collaborative
Wiskott-Aldrich Foundation
Zack Heger Foundation